AKBC member Patheon, by Thermo Fisher Scientific has entered into a strategic partnership with PharmAbcine Inc, a Korean biotech company. PharmAbcine will benefit from Thermo Fisher Scientific’s leading drug development and manufacturing capabilities including their Quick to Clinic™ integrated service offering. Thermo Fisher Scientific will help PharmAbcine progress the development of their drug, PMC-309, and its application for phase 1 clinical trials. PMC-309 is an antibody involved in inhibiting the activity of immune suppressor cells which are implicated in tumour formation.
Dr. Jin-San Yoo, CEO of PharmAbcine, remarked, “we are excited about the progress we have made with PMC-309 and strongly believe that PMC-309 will fulfill the gap in immune-oncology drug landscape.”
PharmAbcine aims to submit their phase 1 application in 2021.
Click here to read more.
Photo credit: shutterstock.com